Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026
Summary
Dizal presented new clinical data for two NSCLC programs at ASCO 2026. DZD6008 showed strong anti-tumor activity, durable responses, brain penetration, and a favorable safety profile in patients who had relapsed after third-generation EGFR TKI treatment. Golidocitinib combined with an anti-PD-1 antibody also showed encouraging efficacy in treatment-naive advanced NSCLC patients without driver mutations. The company says both datasets support further clinical development of its oncology pipeline.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected